AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19113000 — intervention group
Group type: COMPARATOR
Intervention: Manual turning
Number of subjects: 10
Study 19113000 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated turning
Number of subjects: 10
Study 16957067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar damage
Number of subjects: 0
Study 16957067 — intervention group
Group type: COMPARATOR
Intervention: Reactive feedback‐driven motor adaptations
Number of subjects: 0
Study 14990649 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine
Number of subjects: 258
Study 9893184 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy with 7 preseasonal injections of molecular standardized allergens from grass and rye pollen
Number of subjects: 48
Study 8751095 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms TPA
Number of subjects: 10
Study 8751095 — intervention group
Group type: COMPARATOR
Intervention: Buffer solution (control)
Number of subjects: 10
Study 2037323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 54
Study 2037323 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 54
Study 7029275 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of vitamin E per kilogram of body weight per day
Number of subjects: 101
Study 31707245 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion in BD group
Number of subjects: 302
Study 31707245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonattachment to self in BD group
Number of subjects: 302
Study 31707245 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion and depression severity in BD group
Number of subjects: 302
Study 31707245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonattachment to self and depression severity in BD group
Number of subjects: 302
Study 31707245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonattachment to self and hypo/mania symptomology in BD group
Number of subjects: 302
Study 31011868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri 4659 (L. reuteri) plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus L. reuteri/bid for 10 days
Number of subjects: 88
Study 31011868 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus placebo/bid for 10 days
Number of subjects: 88
Study 29078109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health checklist intervention
Number of subjects: 1248
Study 29078109 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no form)
Number of subjects: 1248
Study 27464029 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 11
Study 25274445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian modeling approach for flexible modeling of semicompeting risks data
Number of subjects: 0
Study 25274445 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of illness-death models with flexible random effects
Number of subjects: 0
Study 25274445 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization of shared frailty models
Number of subjects: 0
Study 22312175 — intervention group
Group type: EXPERIMENTAL
Intervention: Loozit intervention with additional therapeutic contact
Number of subjects: 151
Study 22312175 — intervention group
Group type: COMPARATOR
Intervention: Loozit intervention without additional therapeutic contact
Number of subjects: 151
Study 20565984 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of PD one week after catheter insertion
Number of subjects: 0
Study 20565984 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of PD two weeks after catheter insertion
Number of subjects: 0
Study 20565984 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of PD four weeks after catheter insertion
Number of subjects: 0
Study 17345547 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip replacement (MIS group)
Number of subjects: 32
Study 17345547 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgluteal approach (standard group)
Number of subjects: 32
Study 17345547 — intervention group
Group type: COMPARATOR
Intervention: Both surgical groups
Number of subjects: 32
Study 16249665 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (BIS 41-60)
Number of subjects: 48
Study 16249665 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (BIS 61-80)
Number of subjects: 48
Study 16249665 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (BIS 21-40)
Number of subjects: 48
Study 16249665 — intervention group
Group type: COMPARATOR
Intervention: Nonanesthetized subjects
Number of subjects: 48
Study 11919404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 32
Study 11919404 — intervention group
Group type: COMPARATOR
Intervention: Standard Heparin
Number of subjects: 32
Study 10607234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prednisolone/interferon‐alpha2b (IFN‐alpha2b) therapy
Number of subjects: 10
Study 10607234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha2b (IFN‐alpha2b) therapy
Number of subjects: 10
Study 10607234 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 7642417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiation therapy (cisplatin 30 mg/m2 for 3 days, etoposid 80 mg/m2 for 3 days, 5-fluorouracil 900 mg/m2 for 4 days, radiation therapy 2 Gy twice a day for 5 days)
Number of subjects: 47
Study 7642417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiation therapy
Number of subjects: 47
Study 30569502 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 104
Study 28527768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirage sirolimus‐eluting bioresorbable microfiber scaffold
Number of subjects: 60
Study 28527768 — intervention group
Group type: COMPARATOR
Intervention: Absorb bioresorbable vascular scaffold
Number of subjects: 60
Study 25241107 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6-g bolus followed by 2 g/hour infusion for up to 12 hours)
Number of subjects: 1259
Study 25241107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1259
Study 25241107 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate and Placebo
Number of subjects: 1259
Study 24968577 — intervention group
Group type: EXPERIMENTAL
Intervention: Anuloma-viloma
Number of subjects: 60
Study 24968577 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic asanas
Number of subjects: 60
Study 24968577 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study 21489770 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N₂O in oxygen and sevoflurane
Number of subjects: 40
Study 21489770 — intervention group
Group type: COMPARATOR
Intervention: 50% air in oxygen and sevoflurane
Number of subjects: 40
Study 19264239 — intervention group
Group type: EXPERIMENTAL
Intervention: <2-h infusion of eptifibatide
Number of subjects: 624
Study 19264239 — intervention group
Group type: COMPARATOR
Intervention: 18-h infusion of eptifibatide
Number of subjects: 624
Study 17546553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin (0.25 mg/kg b. w. bolus and 0.2 mg/kg b. w. added to the CPB priming)
Number of subjects: 20
Study 17546553 — intervention group
Group type: COMPARATOR
Intervention: Heparin (400 U/kg b. w. bolus with protamine reversal)
Number of subjects: 20
Study 17546553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin
Number of subjects: 20
Study 17546553 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study 15483780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8 g/kg/day) for diabetic patients
Number of subjects: 169
Study 15483780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg/day) for nondiabetic patients
Number of subjects: 169
Study 15483780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet for both diabetic and nondiabetic patients
Number of subjects: 169
Study 15483780 — intervention group
Group type: COMPARATOR
Intervention: Free protein diet for diabetic patients
Number of subjects: 169
Study 15483780 — intervention group
Group type: COMPARATOR
Intervention: Free protein diet for nondiabetic patients
Number of subjects: 169
Study 15483780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet for both groups
Number of subjects: 169
Study 11280671 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg/puff) with low inspiratory flow rate (0.6 l/s)
Number of subjects: 10
Study 11280671 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg/puff) with high inspiratory flow rate (1.2 l/s)
Number of subjects: 10
Study 11280671 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control intervention mentioned)
Number of subjects: 10
Study 9470565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartar-control dentifrice (containing tetrapotassium pyrophosphate, PEG‐6, disodium pyrophosphate, and tetrasodium pyrosulphate in a 5.0% soluble pyrophosphate formulation)
Number of subjects: 38
Study 9470565 — intervention group
Group type: COMPARATOR
Intervention: Regular dentifrice (control group)
Number of subjects: 38
Study 7930696 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-PE40 at 40, 80, or 160 micrograms/m2
Number of subjects: 21
Study 7930696 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-PE40 at 80 micrograms/m2
Number of subjects: 21
Study 7930696 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-PE40 infusions
Number of subjects: 21
Study 7930696 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-PE40
Number of subjects: 21
Study 3150630 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TST) plus chemotherapy
Number of subjects: 51
Study 3150630 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 51
Study 30445939 — intervention group
Group type: EXPERIMENTAL
Intervention: Working for You intervention (adapted from Be Fit Be Well) using automated SMS text messaging for delivery.
Number of subjects: 0
Study 30445939 — intervention group
Group type: COMPARATOR
Intervention: Be Fit Be Well (original intervention)
Number of subjects: 0
Study 27573562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictilisib (260 mg daily on days 1-5 every week) with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Number of subjects: 183
Study 27573562 — intervention group
Group type: COMPARATOR
Intervention: Placebo with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Number of subjects: 183
Study 26571324 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal balancing therapy using a Therapeutic Device for 6 months
Number of subjects: 124
Study 26571324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 124
Study 23536000 — intervention group
Group type: EXPERIMENTAL
Intervention: SU11274
Number of subjects: 80
Study 23536000 — intervention group
Group type: COMPARATOR
Intervention: c-Met expression
Number of subjects: 80
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (high-dose infused over 12 h)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (bolus)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (pancreatic duct injection)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (biliary sphincterotomy)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (intention-to-treat analysis)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (high-dose)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (pancreatic duct injection)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (biliary sphincterotomy)
Number of subjects: 3818
Study 20373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (intention-to-treat analysis)
Number of subjects: 3818
Study 18442357 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-intact soya protein (active treatment)
Number of subjects: 71
Study 18442357 — intervention group
Group type: COMPARATOR
Intervention: Isoflavone-free placebo (control)
Number of subjects: 71
Study 15722803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 185
Study 15722803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention and preventive physical therapy
Number of subjects: 185
Study 15722803 — intervention group
Group type: COMPARATOR
Intervention: Minimal Treatment Group (examination, reassurance, and activity advice)
Number of subjects: 185
Study 12666111 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 10 gm daily
Number of subjects: 175
Study 12666111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 10390133 — intervention group
Group type: COMPARATOR
Intervention: High milk consumption
Number of subjects: 594
Study 10390133 — intervention group
Group type: COMPARATOR
Intervention: High cheese consumption
Number of subjects: 594
Study 10390133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low milk consumption
Number of subjects: 594
Study 10390133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cheese consumption
Number of subjects: 594
Study 10390133 — intervention group
Group type: COMPARATOR
Intervention: Meat or fish intake
Number of subjects: 594
Study 8558219 — intervention group
Group type: COMPARATOR
Intervention: CMFVP (cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 intravenously weekly for 1 year, fluorouracil 400 mg/m2 intravenously weekly for 1 year, vincristine 0.625 mg/m2 intravenously weekly for the first 10 weeks, and prednisone weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2)
Number of subjects: 314
Study 8558219 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP plus bilateral ovariectomy
Number of subjects: 314
Study 8558219 — intervention group
Group type: COMPARATOR
Intervention: CMFVP/CMFVP plus ovariectomy
Number of subjects: 314
Study 2056783 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate (1g/6h)
Number of subjects: 34
Study 2056783 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 6650108 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief courses of antibiotics active against major contaminating bacterial pathogens given prior to surgery
Number of subjects: 0
Study 6650108 — intervention group
Group type: COMPARATOR
Intervention: Long-term administration of antibiotics after surgery
Number of subjects: 0
Study 30845363 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physical activity (PA) monitoring
Number of subjects: 389
Study 29324539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone intervention (Optimal Personalised Care After Treatment-Gynaecological)
Number of subjects: 24
Study 29324539 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital-based follow-up (Control)
Number of subjects: 24
Study 27651394 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational self-management program
Number of subjects: 540
Study 27651394 — intervention group
Group type: COMPARATOR
Intervention: Control group (general psychosocial information)
Number of subjects: 540
Study 27651394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 540
Study 24435063 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote personalized risk communication intervention (TeleCARE)
Number of subjects: 272
Study 24435063 — intervention group
Group type: COMPARATOR
Intervention: Generic print control condition
Number of subjects: 272
Study 23031619 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly mammography and clinical breast examination (Group 1)
Number of subjects: 2000
Study 23031619 — intervention group
Group type: COMPARATOR
Intervention: Yearly MRI and clinical breast examination, and biennial mammography (Group 2)
Number of subjects: 2000
Study 20151052 — intervention group
Group type: COMPARATOR
Intervention: Behavioural therapy
Number of subjects: 3647
Study 20151052 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 3647
Study 17414467 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated multimodality treatment program including a 12-day induction course of radiation (1.5 Gy twice daily to a total of 30 Gy) concurrent with continuous intravenous infusions of cisplatin (20 mg/m2 per day) and 5-fluorouracil (1000 mg/m2 per day), followed by surgery and a second course of chemoradiotherapy.
Number of subjects: 93
Study 17414467 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated multimodality treatment program
Number of subjects: 93
Study 15114104 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 20
Study 15114104 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 20
Study 15114104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HTK and UW solutions
Number of subjects: 20
Study 11599601 — intervention group
Group type: COMPARATOR
Intervention: Marinol (15 mg)
Number of subjects: 4
Study 11599601 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked THC (16.88 mg) in a placebo marijuana cigarette
Number of subjects: 4
Study 11599601 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked marijuana (2.11% THC and 0.12% THCV)
Number of subjects: 4
Study 10984320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone substitution therapy
Number of subjects: 21
Study 10984320 — intervention group
Group type: COMPARATOR
Intervention: Turner syndrome patients
Number of subjects: 21
Study 8055724 — intervention group
Group type: EXPERIMENTAL
Intervention: Toradol (ketorolac tromethamine) injected into the sphincter muscle and taken orally for five days postoperatively
Number of subjects: 63
Study 8055724 — intervention group
Group type: COMPARATOR
Intervention: Narcotics (intramuscular/oral analgesics) after overnight hospital stay
Number of subjects: 63
Study 8055724 — intervention group
Group type: COMPARATOR
Intervention: SQMP (subcutaneous infusion of morphine sulfate via home infusion pump)
Number of subjects: 63
Study 2662688 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline + Tinidazole
Number of subjects: 0
Study 2662688 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 0
Study 233889 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated free fatty acids (C3 to C18) applied daily under occlusive patch tests
Number of subjects: 0
Study 233889 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (C18 unsaturated fatty acid) applied daily under occlusive patch tests
Number of subjects: 0
Study 31937325 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest healthy lifestyle score (HLS)
Number of subjects: 1050
Study 31937325 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest healthy lifestyle score (HLS) in postmenopausal women
Number of subjects: 1050
Study 31937325 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest Healthy Eating Index score (HEI)
Number of subjects: 1050
Study 30153126 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep local anesthesia (group D)
Number of subjects: 68
Study 30153126 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous local anesthesia (group S)
Number of subjects: 68
Study 28419149 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS health promotions and reminders
Number of subjects: 181
Study 24292979 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) combined with microfracture surgery (n=19)
Number of subjects: 35
Study 24292979 — intervention group
Group type: COMPARATOR
Intervention: Microfracture surgery alone (Control group, n=16)
Number of subjects: 35
Study 24672620 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressor-administered defibrillation
Number of subjects: 197
Study 24672620 — intervention group
Group type: COMPARATOR
Intervention: Facilitator-administered defibrillation
Number of subjects: 197
Study 22959807 — intervention group
Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - Arm A: 0.15 mg/kg Foscan; 96 h drug-light interval
Number of subjects: 22
Study 22959807 — intervention group
Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - Arm B: 0.10 mg/kg; 48 h drug-light interval
Number of subjects: 22
Study 22959807 — intervention group
Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - Arm C: 0.075 mg/kg; 24 h drug-light interval
Number of subjects: 22
Study 22959807 — intervention group
Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - All arms
Number of subjects: 22
Study 19374210 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml of hyperbaric S75:R25 bupivacaine (10 mg)
Number of subjects: 40
Study 19374210 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of hyperbaric S75:R25 bupivacaine (12 mg)
Number of subjects: 40
Study 19374210 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of hyperbaric S75:R25 bupivacaine (16 mg)
Number of subjects: 40
Study 19374210 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of hyperbaric S75:R25 bupivacaine (20 mg)
Number of subjects: 40
Study 17542833 — intervention group
Group type: EXPERIMENTAL
Intervention: Air humidification active
Number of subjects: 71
Study 17542833 — intervention group
Group type: COMPARATOR
Intervention: Air humidification inactive (Control)
Number of subjects: 71
Study 15464314 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin D-coated Multilink-Tetra stent (2.5 or 10 microg/cm(2))
Number of subjects: 360
Study 15464314 — intervention group
Group type: COMPARATOR
Intervention: Metallic stent (MS)
Number of subjects: 360
Study 11553222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric interponats
Number of subjects: 0
Study 11553222 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon interponats
Number of subjects: 0